Role of LIM and SH3 protein 1 (LASP1) in the metastatic dissemination of medulloblastoma

Cancer Research

Volumn 70, Issue 20, 2010, Pages 8003-8014

  Traenka, Christopher ^a   Remke, Marc ^b   Korshunov, Andrey ^b   Bender, Sebastian ^b   Hielscher, Thomas ^b   Northcott, Paul A ^c   Witt, Hendrik ^b   Ryzhova, Marina ^d   Felsberg, Jörg ^e   Benner, Axel ^b   Riester, Stephanie ^b   Scheurlen, Wolfram ^f   Grunewald, Thomas G P ^g   Von Deimling, Andreas ^b   Kulozik, Andreas E ^b   Reifenberger, Guido ^e   Taylor, Michael D ^c   Lichter, Peter ^b   Butt, Elke ^a   Pfister, Stefan M ^b,h  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d BURDENKO NEUROSURGICAL INSTITUTE   (Russian Federation)

^e HEINRICH HEINE UNIVERSITY   (Germany)

^f Cnopf'Sche Kinderklinik Nü Rnberg Children's Hospital   (Germany)

^g TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^h NONE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LIM PROTEIN; MESSENGER RNA; PROTEIN SH3; SMALL INTERFERING RNA;

ADOLESCENT; ADULT; ARTICLE; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CHILD; CHROMOSOME 17Q; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ISOCHROMOSOME; LASP 1 ONCOGENE; MAJOR CLINICAL STUDY; MALE; MEDULLOBLASTOMA; METASTASIS; ONCOGENE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CELL ADHESION; CELL LINE, TUMOR; CEREBELLAR NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 17; CYTOSKELETAL PROTEINS; GENE EXPRESSION PROFILING; GENE SILENCING; HOMEODOMAIN PROTEINS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MEDULLOBLASTOMA; NEOPLASM METASTASIS; RNA, MESSENGER; RNA, NEOPLASM; RNA, SMALL INTERFERING; TRANSFECTION; UP-REGULATION;

EID: 78049242921     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-0592     Document Type: Article

References (49)

1. Louis D, Ohgaki H, Wiestler O, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97-109. (Pubitemid 47103521)
2. Zeltzer PM, Boyett JM, Finlay JL, et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medullo blastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol 1999;17:832-45.
3. Zerbini C, Gelber R, Weinberg D, et al. Prognostic factors in medulloblastoma, including DNA ploidy. J Clin Oncol 1993;11:616-22. (Pubitemid 23105668)
4. Thompson MC, Fuller C, Hogg TL, et al. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol 2006;24:1924-31. (Pubitemid 46638992)
5. Kool M, Koster J, Bunt J, et al. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One 2008;3:e3088.
6. Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol. Epub 2010 Sep 7.
7. Ellison DW, Onilude OE, Lindsey JC, et al, The United Kingdom Children's Cancer Study Group Brain Tumour Committee. β-Catenin status predicts a favorable outcome in childhood medulloblastoma. J Clin Oncol 2005;23:7951-7.
8. Clifford S, Lusher M, Lindsey J, et al. Wnt/wingless pathway activation and chromosome 6 loss characterise a distinct molecular subgroup of medulloblastomas associated with a favourable prognosis. Cell Cycle 2006;5:2666-70.
9. Gajjar A, Chintagumpala M, Ashley D, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol 2006;7:813-20.
10. Pizer BL, Clifford SC. The potential impact of tumour biology on improved clinical practice for medulloblastoma: progress towards biologically driven clinical trials. Br J Neurosurg 2009;23:364-75.
11. Pfister S, Remke M, Benner A, et al. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q, 17q, and the MYC/MYCN loci. J Clin Oncol 2009;27:1627-36.
12. Raffel C, Jenkins RB, Frederick L, et al. Sporadic medulloblastomas contain PTCH mutations. Cancer Res 1997;57:842-5. (Pubitemid 27098006)
13. Pietsch T, Waha A, Koch A, et al. Medulloblastomas of the desmoplastic variant carry mutations of the human homologue of Drosophila patched. Cancer Res 1997;57:2085-8.
14. Taylor MD, Liu L, Raffel C, et al. Mutations in SUFU predispose to medulloblastoma. Nat Genet 2002;31:306-10.
15. Scheurlen WG, Schwabe GC, Joos S, Mollenhauer J, Sorensen N, Kuhl J. Molecular analysis of childhood primitive neuroectodermal tumors defines markers associated with poor outcome. J Clin Oncol 1998;16:2478-85.
16. Mendrzyk F, Radlwimmer B, Joos S, et al. Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma. J Clin Oncol 2005;23:8853-62. (Pubitemid 46211532)
17. Northcott PA, Nakahara Y, Wu X, et al. Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. Nat Genet 2009;41:465-72.
18. Korshunov A, Benner A, Remke M, Lichter P, von Deimling A, Pfister S. Accumulation of genomic aberrations during clinical progression of medulloblastoma. Acta Neuropathol 2008;116:383-90.
19. Gilbertson RJ, Perry RH, Kelly PJ, Pearson ADJ, Lunec J. Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res 1997;57:3272-80. (Pubitemid 27351746)
20. Fangusaro J, Jiang Y, Holloway M, et al. Survivin, survivin-2B, and survivin-deItaEx3 expression in medulloblastoma: biologic markers of tumour morphology and clinical outcome. Br J Cancer 2005;92:359-65. (Pubitemid 40343153)
21. Tomasetto C, Regnier C, Moog-Lutz C, et al. Identification of four novel human genes amplified and overexpressed in breast carcinoma and localized to the q11-21.3 region of chromosome 17. Genomics 1995;28:367-76.
22. Grunewald TG, Butt E. The LIM and SH3 domain protein family: structural proteins or signal transducers or both? Mol Cancer 2008;7:31.
23. Grunewald TG, Kammerer U, Schulze E, et al. Silencing of LASP-1 influences zyxin localization, inhibits proliferation and reduces migration in breast cancer cells. Exp Cell Res 2006;312:974-82.
24. Grunewald TG, Kammerer U, Winkler C, et al. Overexpression of LASP-1 mediates migration and proliferation of human ovarian cancer cells and influences zyxin localisation. Br J Cancer 2007;96:296-305. (Pubitemid 46160635)
25. Grunewald TG, Kammerer U, Kapp M, et al. Nuclear localization and cytosolic overexpression of LASP-1 correlates with tumor size and nodal-positivity of human breast carcinoma. BMC Cancer 2007;7:198.
26. Tomasetto C, Moog-Lutz C, Regnier CH, Schreiber V, Basset P, Rio MC. Lasp-1 (MLN 50) defines a new LIM protein subfamily characterized by the association of LIM and SH3 domains. FEBS Lett 1995;373:245-9.
27. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001;29:e45.
28. Butt E, Gambaryan S, Gottfert N, Galler A, Marcus K, Meyer HE. Actin binding of human LIM and SH3 protein is regulated by cGMP-and cAMP-dependent protein kinase phosphorylation on serine 146. J Biol Chem 2003;278:15601-7. (Pubitemid 36799669)
29. Sun HJ, Bahk YY, Choi YR, Shim JH, Han SH, Lee JW. A proteomic analysis during serial subculture and osteogenic differentiation of human mesenchymal stem cell. J Orthop Res 2006;24:2059-71.
30. Korn EL. Censoring distributions as a measure of follow-up in survival analysis. Stat Med 1986;5:255-60.
31. Tarca AL, Draghici S, Khatri P, et al. A novel signaling pathway impact analysis. Bioinformatics 2009;25:75-82.
32. Trojanowski JQ, Friedman HS, Burger PC, Bigner DD. A rapidly dividing human medulloblastoma cell line (D283 MED) expresses all three neurofilament subunits. Am J Pathol 1987;126:358-63.
33. Hislop RG, Pratt N, Stocks SC, et al. Karyotypic aberrations of chromosomes 16 and 17 are related to survival in patients with breast cancer. Br J Surg 2002;89:1581-6. (Pubitemid 35404329)
34. Dimova I, Orsetti B, Negre V, et al. Genomic markers for ovarian cancer at chromosomes 1, 8 and 17 revealed by array CGH analysis. Tumori 2009;95:357-66.
35. Neo S, Leow C, Vega V, et al. Identification of discriminators of hepatoma by gene expression profiling using a minimal dataset approach. Hepatology 2004;39:944-53. (Pubitemid 38428933)
36. Viney RL, Morrison AA, van den Heuvel LP, et al. A proteomic investigation of glomerular podocytes from a Denys-Drash syndrome patient with a mutation in the Wilms tumour suppressor gene WT1. Proteomics 2007;7:804-15.
37. Li Z, Szabolcs M, Terwilliger JD, Efstratiadis A. Prostatic intraepithelial neoplasia and adenocarcinoma in mice expressing a probasin-Neu oncogenic transgene. Carcinogenesis 2006;27:1054-67.
38. Wang B, Feng P, Xiao Z, Ren EC. LIM and SH3 protein 1 (Lasp1) is a novel p53 transcriptional target involved in hepatocellular carcinoma. J Hepatol 2009;50:528-37.
39. Frietsch JJ, Grunewald TG, Jasper S, et al. Nuclear localisation of LASP-1 correlates with poor long-term survival in female breast cancer. Br J Cancer 2010;102:1645-53.
40. Turner DP, Findlay VJ, Kirven AD, Moussa O, Watson DK. Global gene expression analysis identifies PDEF transcriptional networks regulating cell migration during cancer progression. Mol Biol Cell 2008;19:3745-57.
41. Sood AK, Saxena R, Groth J, et al. Expression characteristics of prostate-derived Ets factor support a role in breast and prostate cancer progression. Hum Pathol 2007;38:1628-38. (Pubitemid 47589085)
42. Smith SC, Theodorescu D. Learning therapeutic lessons from metastasis suppressor proteins. Nat Rev Cancer 2009;9:253-64.
43. Liu R, Wang X, Chen GY, et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 2007;356:217-26. (Pubitemid 46143225)
44. Martin TA, Harrison G, Mansel RE, Jiang WG. The role of the CD44/ezrin complex in cancer metastasis. Crit Rev Oncol Hematol 2003;46:165-86. (Pubitemid 36452345)
45. Wagner W, Horn P, Castoldi M, et al. Replicative senescence of mesenchymal stem cells: a continuous and organized process. PLoS One 2008;3:e2213.
46. Osawa H, Smith CA, Ra YS, Kongkham P, Rutka JT. The role of the membrane cytoskeleton cross-linker ezrin in medulloblastoma cells. Neuro-oncol 2009;11:381-93.
47. Gray CH, McGarry LC, Spence HJ, Riboldi-Tunnicliffe A, Ozanne BW. Novel β-propeller of the BTB-Kelch protein Krp1 provides a binding site for Lasp-1 that is necessary for pseudopodial extension. J Biol Chem 2009;284:30498-507.
48. Rachlin AS, Otey CA. Identification of palladin isoforms and characterization of an isoform-specific interaction between Lasp-1 and palladin. J Cell Sci 2006;119:995-1004.
49. Grunewald TG, Pasedag SM, Butt E. Cell adhesion and transcriptional activity - defining the role of the novel protooncogene LPP. Transl Oncol 2009;2:107-16.